Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P49448
UPID:
DHE4_HUMAN
Alternative names:
-
Alternative UPACC:
P49448; B2R8G0; Q9UDQ4
Background:
Glutamate dehydrogenase 2, mitochondrial, plays a pivotal role in neurotransmission by recycling glutamate, the primary excitatory neurotransmitter. Its activity within the mitochondria is crucial for maintaining the balance of glutamate levels in the brain.
Therapeutic significance:
Understanding the role of Glutamate dehydrogenase 2, mitochondrial could open doors to potential therapeutic strategies. Its critical function in neurotransmitter recycling highlights its potential as a target for modulating neurotransmission in various neurological conditions.